Cartesian Therapeutics (RNAC) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed Sionna Therapeutics (SION) over the past year, losing 31.4% versus a loss of 83.2%. Sionna Therapeutics is the larger company by market cap ($217.6 million vs $202.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | SION |
|---|---|---|
| Share price | $6.68 | $4.82 |
| Market cap | $202.11M | $217.62M |
| 1-day change | -1.04% | +1.47% |
| YTD return | -7.35% | -88.28% |
| 1-year return | -31.42% | -83.15% |
| 5-year return | -94.79% | — |
| EPS (TTM) | $-5.78 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.00 | $54.97 |
| 52-week low | $5.60 | $4.01 |
| Distance from 52-week high | -39.27% | -91.23% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +404.04% | +335.68% |
| Average volume | 132.71K | 2.18M |
| Shares outstanding | 30.26M | 45.15M |
| Employees | 75 | 59 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNAC has outperformed SION by 51.7 percentage points over the past year.
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Healthcare · Biotechnology · 59 employees
RNAC vs SION FAQ
Which is bigger, Cartesian Therapeutics or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $217.62M compared with $202.11M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, RNAC or SION?
RNAC returned -31.42% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.